An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

A new study suggests Paxlovid may not reduce the risk of covid-19 hospitalizations and all-cause deaths in vaccinated adults ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

That’s very different from the results that Paxlovid’s maker, Pfizer, first reported in 2022. In that study, Pfizer found that the drug reduced hospitalizations and deaths from COVID-19 by 89% ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

“I think that needs to be part of the conversation.” A spokesperson for Pfizer, which makes Paxlovid, said the company stands ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the ...

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...

Paxlovid - Pfizer’s combination of nirmatrelvir and ritonavir - has been found to reduce symptoms, hospitalizations and deaths in unvaccinated, at-risk patients. However, a Pfizer trial ...

“I think that needs to be part of the conversation.” A spokesperson for Pfizer, which makes Paxlovid, said the company stands by its effectiveness for patients at high risk for severe illnes ...